Covariate-adjusted posterior probabilities that gemtuzumab ozogamicin (GO) with or without interleukin 11 (IL-11) was associated with a shorter survival than idarubicin plus cytosine arabinoside (IA)
| Assumed trial effect, posterior mean (SD) . | Posterior probability that GO with or without IL-11 was inferior to IA . | ||
|---|---|---|---|
| Normal cytogenetic findings . | Cytogenetic finding of −5/−7 . | Other cytogenetic abnormalities . | |
| 0.396 (0.318) | 0.832 | 0.9997 | 0.988 |
| −0.396 (0.318) | 0.997 | 1.000 | 0.999 |
| 0.328 (0.291) | 0.868 | 0.998 | 0.991 |
| −0.328 (0.291) | 0.995 | 1.000 | 1.000 |
| Assumed trial effect, posterior mean (SD) . | Posterior probability that GO with or without IL-11 was inferior to IA . | ||
|---|---|---|---|
| Normal cytogenetic findings . | Cytogenetic finding of −5/−7 . | Other cytogenetic abnormalities . | |
| 0.396 (0.318) | 0.832 | 0.9997 | 0.988 |
| −0.396 (0.318) | 0.997 | 1.000 | 0.999 |
| 0.328 (0.291) | 0.868 | 0.998 | 0.991 |
| −0.328 (0.291) | 0.995 | 1.000 | 1.000 |